entX is proud to be part of "Project Alpha 10.6", a major UK initiative aimed at establishing a globally significant and sustainable source of precursors for 212Pb - the pre-eminent cancer-killing payload for emerging radioimmunotherapies.

Project Alpha 10.6 is a vital stepping-stone in unlocking an ultra-reliable UK source of therapeutic isotope precursor. entX is delighted to be taking part and looks forward to contributing to the project by providing 212Pb-specific isotope handling data from its newly installed pre-clinical 212Pb laboratory in Adelaide (AU) with a view to becoming the commercialisation partner for isotope distribution in the future. Specifically, entX will share information on safe processes for milking and packaging 212Pb at activity levels suitable for preclinical studies.

Project Alpha 10.6 is led by the United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC).

The full Consortium comprises: PentaBind, Iksuda Therapeutics, Cyclife Aquila Nuclear, Seda Pharmaceutical Development & Clinical Manufacturing Services and entX Limited.

The project is funded (for UK parties) through the 'Sustainable Medicines Manufacturing - Grand Challenge' managed by Innovate UK.

Read the full announcement: https://uknnl.com/2025/11/uk-nuclear-revolution-powers-next-generation-precision-cancer-therapies/